802 results on '"Sarpatwari A"'
Search Results
2. Independent Advice on Drug Approvals: an Investigation of EMA Practices
3. The implications of Industry-Funded Disease Awareness Campaigns in the Rare Disease Setting
4. Hydroxyzine Initiation Following Drug Safety Advisories on Cardiac Arrhythmias in the UK and Canada: A Longitudinal Cohort Study
5. State Laws and Generic Substitution in the Year After New Generic Competition
6. Thromboelastometry Predicts Thromboembolic Events, Hospital Length of Stay, and Mortality in Patients with COVID-19 Infection and Mild Hypoxemia: A Prospective Observational Study
7. Analysis of risk evaluation and mitigation strategies for teratogenic drugs: Variation in primary and secondary prevention measures.
8. Physician experiences with and perceptions of risk evaluation and mitigation strategy programs with elements to assure safe use.
9. The characteristics of patents impacting availability of biosimilars
10. Preventing Medical Device-Borne Outbreaks
11. Commercial markups on pediatric oncology drugs at 340B pediatric hospitals.
12. Patent Portfolios Protecting 10 Top-Selling Prescription Drugs.
13. Accounting for US public funding in drug development : how can we better balance access, affordability, and innovation?
14. How Do Risk Evaluation and Mitigation Strategies Impact Clinical Practice? A National Survey of Physicians
15. A Multi-modal Approach to Evaluate the Impact of Risk Evaluation and Mitigation Strategy (REMS) Programs
16. Analysis of risk evaluation and mitigation strategies for teratogenic drugs: Variation in primary and secondary prevention measures
17. Biosimilar Uptake In The US: Patient And Prescriber Factors
18. Identifying potential prescription drug product hopping
19. Changes in Erythropoiesis Stimulating Agent Use Under a Risk Evaluation and Mitigation Strategy (REMS) Program
20. Federal Trade Commission Actions on Prescription Drugs, 2000-2022.
21. Estimated Medicare Part D Savings From Generic Drugs With a Skinny Label.
22. Outcomes of the 340B Drug Pricing Program
23. Changes in Induced Medical and Procedural Abortion Rates in a Commercially Insured Population, 2018 to 2022
24. Independent Advice on Drug Approvals: an Investigation of EMA Practices
25. A qualitative study of biosimilar manufacturer and regulator perceptions on intellectual property and abbreviated approval pathways
26. Physician experiences with and perceptions of risk evaluation and mitigation strategy programs with elements to assure safe use
27. Novelty of Active Ingredients in High-Cost Brand-Name Drugs
28. FDA and EMA Biosimilar Approvals
29. Impact of State Laws Restricting Opioid Duration on Characteristics of New Opioid Prescriptions
30. Disease pathogenesis, treatment effectiveness, and co-morbid burden among adult patients with primary immune thrombocytopenia (ITP)
31. A Survey of Patients’ Perceptions of Pill Appearance and Responses to Changes in Appearance for Four Chronic Disease Medications
32. Effect of Lawyer-Submitted Reports on Signals of Disproportional Reporting in the Food and Drug Administration’s Adverse Event Reporting System
33. State Laws and Generic Substitution in the Year After New Generic Competition
34. A 'Method of Use' to Prevent Generic and Biosimilar Market Entry
35. The Bayh-Dole Act at 40: Accomplishments, Challenges, and Possible Reforms
36. Public Returns on Public Investment: Moderna's Violation of the Social Contract.
37. Transparency on Prescription Drug Research Expenditures
38. Unwanted Advice? Frequency, Characteristics, And Outcomes Of Negative Advisory Committee Votes For FDA-Approved Drugs
39. Indication-Specific Generic Uptake of Imatinib Demonstrates the Impact of Skinny Labeling
40. US public investment in development of mRNA covid-19 vaccines: retrospective cohort study
41. A “Method of Use” to Prevent Generic and Biosimilar Market Entry
42. The 340B Drug Pricing Program: Litigation, Administration, and Reform
43. Frequency of Approval and Marketing of Biosimilars With a Skinny Label and Associated Medicare Savings
44. INTRODUCTION: Promoting Drug and Vaccine Innovation and Managing High Prices: Introducing a Special Symposium
45. Competition and price among brand-name drugs in the same class: A systematic review of the evidence.
46. Comparative effectiveness of generic and brand-name medication use: A database study of US health insurance claims.
47. Patents on Risk Evaluation and Mitigation Strategies for Prescription Drugs and Generic Competition.
48. Improving the Use of FDA Advisory Committees
49. The characteristics of patents impacting availability of biosimilars
50. High-Priced Sickle Cell Gene Therapies Threaten to Exacerbate US Health Disparities and Establish New Pricing Precedents for Molecular Medicine
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.